Related Experiment Video
Updated: Jul 4, 2026
08:33
Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay
Published on: June 25, 2019
Parkinson patient fibroblasts show increased alpha-synuclein expression
Hans-Hermann Hoepken1, Suzana Gispert, Mekhman Azizov
1Department of Neurology, University Medical School, Frankfurt am Main, Germany.
Experimental Neurology
|May 31, 2008
Summary
Loss of PINK1 function in Parkinson's disease (PD) leads to increased alpha-synuclein (SNCA) expression, a potential biomarker for PD diagnosis. This finding links mitochondrial dysfunction to neurodegeneration.
Area of Science:
- Neuroscience
- Genetics
- Cell Biology
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder often linked to oxidative stress.
- Increased alpha-synuclein (SNCA) expression is implicated in rare forms of PD.
- PINK1 (PTEN-induced kinase 1) mutations causing PARK6 lead to mitochondrial dysfunction and oxidative damage.
Purpose of the Study:
- To elucidate the molecular pathway from mitochondrial dysfunction to cell death in PD.
- To investigate the link between PINK1 deficiency and alpha-synuclein (SNCA) expression.
- To identify potential biomarkers for PD diagnosis.
Main Methods:
- Analysis of gene expression in primary skin fibroblast cultures from PD patients with G309D-PINK1 mutations.
- PINK1 knockdown in control fibroblasts.
- Exposure of control fibroblasts to oxidative, proteasomal, and endoplasmic reticulum stress.
Main Results:
- Fibroblasts from G309D-PINK1 patients showed altered expression of oxidative stress-related genes and SNCA.
- PINK1 knockdown in control cells induced SNCA expression.
- SNCA induction was observed in sporadic PD patient fibroblasts, suggesting it as a biomarker.
- Various cellular stresses (oxidative, proteasomal, ER) could trigger SNCA upregulation.
Conclusions:
- Loss-of-function mutations in PINK1 enhance alpha-synuclein (SNCA) expression.
- SNCA induction may be a common mechanism across different PD variants and a trigger for neurodegeneration.
- Observed gene expression changes in peripheral tissues could serve as objective biomarkers for PD diagnosis.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...